 |
  
Pharmaceutical Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Tripos Gets $90 Million From Pfizer Inc. CollaborationPress Release November 26, 2005 ST. LOUIS--(BUSINESS WIRE)--Nov. 23, 2005--Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that its file enrichment collabo ration with Pfizer Inc. (NYSE:PFE) will conclude in December 2005. This will complete Tripos' work on Pfizer's library collection. Under the terms of the agreement, Tripos received approximately $90 million over the four-year project for the design, synthesis and purification of drug-like compounds, hit follow-up and large library production. "This was a very productive relationship, and the knowledge and experience we have gained through our work with Pfizer during the past four years will benefit our existing and future customers with whom we continue to discover and develop new drug candidates," said Dr. John P. McAlister, president and CEO of Tripos. "As our Pfizer collaboration draws to an end, we remain committed to our Discovery Research business, as evidenced by our significant investment in Tripos Discovery Research and our new LeadDiscovery program." "We are evaluating the level of resources necessary to build high-value discovery research collaborations with our customers, and anticipate a reorganization of Tripos Discovery Research may be necessary," McAlister said. "We will carefully review staff levels to ensure we can continue to deliver the highest-quality service without impacting our existing and developing collaborations. Tripos Discovery Informatics (our software business) is not impacted by the Pfizer file enrichment contract completion, and existing informatics contracts with Pfizer are unaffected." For more than a quarter of a century, Tripos has been pioneering breakthroughs in drug discovery through its proprietary informatics and research technologies. Tripos Discovery Research offers high-value drug discovery collaborations for the pharmaceutical and biotechnology industry. It has ongoing collaborations with leading pharmaceutical and biotechnology companies and a developing pipeline of new business. Tripos' LeadDiscovery program, launched this summer, offers a new way for companies to partner with Tripos to develop novel pre-clinical compounds with proven potency, selectivity, and the potential to own intellectual property in the areas of G-protein-coupled receptors and kinases. General This press release contains forward-looking statements concerning, among other things: (1) expectations regarding future revenues and earnings, product introductions, growth in product sales, resource allocation and capacity; (2) expectations regarding existing and future opportunities for drug discovery collaborations; and (3) expectations regarding the success of Tripos' LeadDiscovery program. These statements are based upon numerous assumptions which Tripos cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, without limitations, those factors set forth in the Company's Form 10-K for the fiscal year ended December 31, 2004, and from time to time in the Company's periodic filings with the Securities and Exchange Commission. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise. About Tripos, Inc. Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Further information on Tripos can be found at http://www.tripos.com. Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. Contacts Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Worldwide Bioscience and Healthcare Practice Lisa Osborne, 202-326-0973 (Media only) lisao@WaggenerEdstrom.com
About hireRx
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page
Print This Page